with Merck, known as MSD outside ...
Sutro Biopharma, in collaboration with Merck, dosed the first patient in a Phase 1 study for a novel cytokine derivative therapeutic targeting cancer, triggering a $10 million payment to Sutro. This milestone highlights the synergy between Merck's immuno-oncology expertise and Sutro's biologics engineering capabilities.
Reference News
with Merck, known as MSD outside ...
Sutro Biopharma, in collaboration with Merck, dosed the first patient in a Phase 1 study for a novel cytokine derivative therapeutic targeting cancer, triggering a $10 million payment to Sutro. This milestone highlights the synergy between Merck's immuno-oncology expertise and Sutro's biologics engineering capabilities.